COVID-19 vaccination in pregnancy: early experience from a single institution
- PMID: 34411758
- PMCID: PMC8366042
- DOI: 10.1016/j.ajogmf.2021.100464
COVID-19 vaccination in pregnancy: early experience from a single institution
Abstract
Objective: Pregnant women are at increased risk for morbidity owing to infection with the COVID-19 virus.1 Vaccination presents an important strategy to mitigate illness in this population. However, there is a paucity of data on vaccination safety and pregnancy outcomes because pregnant women were excluded from the initial phase III clinical trials. Our objective was to describe the maternal, neonatal, and obstetrical outcomes of women who received a messenger RNA (mRNA) COVID-19 vaccination while pregnant during the first 4 months of vaccine availability.
Study design: This was an institutional review board-approved descriptive study of pregnant women at New York University Langone Health who received at least 1 dose of an mRNA COVID-19 vaccination approved by the US Food and Drug Administration (FDA) (Pfizer-BioNTech or Moderna) from the time of the FDA Emergency Use Authorization to April 22, 2021. Eligible women were identified via search of the electronic medical record (EMR) system. Vaccine administration was ascertained via immunization records from the New York State Department of Health. Women were excluded if they were vaccinated before conception or during the postpartum period. Charts were reviewed for maternal demographics and pregnancy outcomes. Descriptive analyses were performed using the R software version 4.0.2 (The R Foundation, Boston, MA).
Results: We identified 424 pregnant women who received an mRNA vaccination. Of those, 348 (82.1%) received both doses and 76 (17.9%) received only 1 dose. The maternal characteristics and vaccination information are shown in Table 1. Of the included women, 4.9% had a history of a confirmed COVID-19 diagnosis before vaccination. After vaccination, no patient in our cohort was diagnosed with COVID-19. In terms of the pregnancy outcomes, 9 women had spontaneous abortions, 3 terminated their pregnancies, and 327 have ongoing pregnancies. Of the women included, 85 delivered liveborn infants. There were no stillbirths in our population. Of the 9 spontaneous abortions, 8 occurred during the first trimester at a range of 6 to 13 weeks' gestation. There was 1 second trimester loss. The rate of spontaneous abortion among women vaccinated in the first trimester was 6.5%. The 327 women with ongoing pregnancies have been followed for a median of 4.6 weeks (range, 0-17 weeks) following their most recent dose. A total of 113 (34.6%) women, initiated vaccination during the first trimester, 178 (54.4%) initiated vaccination during the second trimester, and 36 (11.0%) during the third trimester. Following the vaccination, 2 fetuses (0.6%) developed intrauterine growth restriction, whereas 5 (1.5%) were diagnosed with anomalies. Outcomes for the 85 women who delivered are shown in Table 2. Of the women who delivered, 18.8% were diagnosed with a hypertensive disorder of pregnancy. The rate of preterm birth was 5.9%. One preterm delivery was medically indicated, whereas the remaining 3 were spontaneous. A total of 15.3% of neonates required admission to the neonatal intensive care unit (NICU). Of the NICU admissions, 61.5% were because of hypoglycemia or an evaluation for sepsis. Other reasons for admission included prematurity, hypothermia, and transient tachypnea of the newborn. Of all the neonates, 12.2% were small for gestational age (SGA) per the World Health Organization standards.
Conclusion: This series describes our experience with women who received an mRNA COVID-19 vaccine during pregnancy. In line with other published findings,2 we observed no concerning trends. There were no stillbirths. Our 6.5% rate of spontaneous abortion is within the expected rate of 10%,3 and our preterm birth rate of 5.9% is below the national average of 9.5%.4 Our rate of pregnancy-related hypertensive disorders is higher than our baseline institutional rate of 9.5%, however, this may be because of the underlying characteristics of our study population or skewing of our small sample size. Our 12.2% rate of SGA neonates is near the expected value based on the definition that 10% of neonates will be SGA at birth. The NICU admission rate is at par with our institutional rate of 12%. To date, most women in this series have had uncomplicated pregnancies and have delivered at-term. Strengths of this study include using the EMR system to identify subjects and gather data. We did not rely on self-enrollment and self-report, thereby reducing selection and recall bias. By performing manual chart reviews, we obtained detailed and reliable information about individual patients. One limitation of this study is the lack of a matched control group consisting of unvaccinated pregnant women and therefore direct conclusions could not be drawn about the relative risks of complications. In addition, our cohort is small and may not be generalizable. Finally, many women included are healthcare workers who had early access to vaccinations. As more pregnant women become eligible for the COVID-19 vaccinations, there is an urgent need to report on the maternal, neonatal, and obstetrical outcomes of COVID-19 vaccinations during pregnancy. The results of this study can be used to counsel and reassure pregnant patients facing this decision.
Copyright © 2021 Elsevier Inc. All rights reserved.
Comment in
-
Approximation and evaluation of the spontaneous abortion rate following COVID-19 vaccination in pregnancy.Am J Obstet Gynecol MFM. 2022 Jan;4(1):100510. doi: 10.1016/j.ajogmf.2021.100510. Epub 2021 Oct 14. Am J Obstet Gynecol MFM. 2022. PMID: 34656736 Free PMC article. No abstract available.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
COVID-19 vaccination during pregnancy: coverage and safety.Am J Obstet Gynecol. 2022 Feb;226(2):236.e1-236.e14. doi: 10.1016/j.ajog.2021.08.007. Epub 2021 Aug 10. Am J Obstet Gynecol. 2022. PMID: 34389291 Free PMC article.
-
Pregnancy and infant outcomes following SARS-CoV-2 infection in pregnancy during delta variant predominance - Surveillance for Emerging Threats to Pregnant People and Infants.Am J Obstet Gynecol MFM. 2024 Feb;6(2):101265. doi: 10.1016/j.ajogmf.2023.101265. Epub 2023 Dec 21. Am J Obstet Gynecol MFM. 2024. PMID: 38135220 Free PMC article.
-
Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: A systematic review and meta-analysis.Rev Med Virol. 2023 May;33(3):e2434. doi: 10.1002/rmv.2434. Epub 2023 Mar 10. Rev Med Virol. 2023. PMID: 36896895 Review.
-
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.Vaccine. 2024 Apr 2;42(9):2380-2384. doi: 10.1016/j.vaccine.2024.02.084. Epub 2024 Mar 11. Vaccine. 2024. PMID: 38462432 Review.
Cited by
-
Maternal COVID-19 vaccination status and association with neonatal congenital anomalies.Front Pediatr. 2024 Apr 19;12:1355502. doi: 10.3389/fped.2024.1355502. eCollection 2024. Front Pediatr. 2024. PMID: 38706924 Free PMC article.
-
COVID-19 vaccination in pregnancy: A review of maternal and infant benefits.Gynecol Obstet Clin Med. 2022 Sep;2(3):124-128. doi: 10.1016/j.gocm.2022.07.003. Epub 2022 Aug 9. Gynecol Obstet Clin Med. 2022. PMID: 38620770 Free PMC article. Review.
-
Efficacy and Clinical Outcomes of mRNA COVID-19 Vaccine in Pregnancy: A Systematic Review and Meta-Analysis.Intervirology. 2024;67(1):40-54. doi: 10.1159/000538135. Epub 2024 Mar 2. Intervirology. 2024. PMID: 38432215 Free PMC article.
-
Being Pregnant during COVID-19: Exploring the COVID-19 Related Beliefs, Behaviors, and Birth Outcome among Users of a Pregnancy App.Int J Environ Res Public Health. 2023 Dec 26;21(1):34. doi: 10.3390/ijerph21010034. Int J Environ Res Public Health. 2023. PMID: 38248499 Free PMC article.
-
COVID-19 Vaccination and Abnormal Blood Glucose Level.Adv Biomed Res. 2023 Nov 29;12:258. doi: 10.4103/abr.abr_195_23. eCollection 2023. Adv Biomed Res. 2023. PMID: 38192882 Free PMC article. No abstract available.
References
-
- American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology ACOG Practice Bulletin No. 200: early pregnancy loss. Obstet Gynecol. 2018;132 e197–207.
-
- Ferré C, Callaghan W, Olson C, Sharma A, Barfield W. Effects of maternal age and age-specific preterm birth rates on overall preterm birth rates—United States, 2007 and 2014. MMWR Morb Mortal Wkly Rep. 2016;65:1181–1184. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous